[HIV-STD-Prevention] Weekly Prevention Resources - 5/7/25 #u#

Wed May 7 14:01:45 PDT 2025

Hello, HIV and STI Prevention partners,

Welcome to this week’s HIV/STI Prevention listserv email! Please email me at shelley.m.pearson at oha.oregon.gov<mailto:shelley.m.pearson at oha.oregon.gov> with any feedback about the listserv, with announcements/resources to share, or if you have colleagues who would like to be added to the list. For more information about the resources shared, please reach out via the contact information on each item.

In this week’s email:

  *   STI Update: Congenital Syphilis and Syphilis in Pregnancy Live Webinar with Dr. Tim Menza, May 22 (with attached pdf)
  *   2025 National HIV Testing Day with KFF’s Greater Than and Walgreens (including webinar on May 22)
  *   CDC Releases Updated Recommendations for HIV Nonoccupational Postexposure Prophylaxis

________________________________

Clackamas County is partnering with the University of Washington’s STD Prevention and Training Center to offer a free CME accredited training on congenital syphilis and syphilis in pregnancy with Dr. Tim Menza. See the attached pdf to learn more and register.

________________________________

2025 National HIV Testing Day activation with KFF’s Greater Than and Walgreens<http://greaterthan.org/walgreens>.

This year marks 15 years of collaborating with local health departments, testing organizations, and Walgreens stores to expand free HIV/STD testing in communities across all 50 states! To show our appreciation, we’d like to send your organization a package of Knowledge is Power informational palm cards and buttons. Your agency will receive one package with enough materials to share with colleagues. Please take a moment to fill out this short form to confirm your mailing address<https://docs.google.com/forms/d/e/1FAIpQLSdnpjR9WcLT19D0l2g6YU_2YMFeWj5b4hD8ehPHDtZ3_lgzQg/viewform?usp=sharing> by the end of this week. Note: if you cannot access google forms, feel free to respond to this email with your best mailing address and phone number.

We look forward to getting these materials to you in early June.

Thank you for the partnership!
Allison & the Greater Than team

P.S. Don’t forget to register yourself<https://kff-org.zoom.us/webinar/register/WN_99qsL_jbSQ6yGU8Pf8OhNg#/registration> <https://kff-org.zoom.us/webinar/register/WN_99qsL_jbSQ6yGU8Pf8OhNg#/registration> (and your colleagues in Communications!) for the NHTD Webinar "Getting the Word Out" on Thursday, May 22.

Allison Dejan (she/her/hers)
Consultant, KFF’s Greater Than

New Orleans

504.444.1896

allisond at kff.org<mailto:allisond at kff.org>

________________________________

[https://files.constantcontact.com/980d1efb101/d7beea56-43f5-4323-8663-8435ee4940bb.png?rdr=true]

CDC Releases Updated Recommendations for HIV Nonoccupational Postexposure Prophylaxis, United States, 2025

View Full Recommendations<https://jeud54gab.cc.rs6.net/tn.jsp?f=001-7EhbBdSupsnaD1lwRUP5h3I6uUPSHxAJ2g3MFNUqcxNpTmfHKKV46cqA32fZrCBmcBZzm4ywKyynvOicehb1cWKGLOLru5hj0Dk7xdR7-rLs2aXKok_2xshka5i-RjySL9Xus8UjUSOnblBG0mlNGOryzyPIp-hUM94zs6Cub9tIxshtrVjp0_TEoU7jNca9yEC9P2FhQ_F2v9esntrEr7gJzzSOX8VQSMW9W0T7-g6cFdROa63GMbdozKo8YJhfGn6Gn73YHTBbaqi1kIjrpYiQ7wFt4s0TdCDkO7F0aEySCVIY7D66iXaKTgZXAtnpmrpWFOtatb6Fgm2092Mf-lCbfhM0RSuJhWujZ44BQWVhH1jq19qOtlneGL_IHnQvAvkVOhKp30h0PW4xgHF48IIwf0Yho3RrWdQyjCIWgTUQCr1GOYYWun9O29gYWpU7Q5grUDvIH01nY84Zvcw1Tl0AVAZCyxH1T_6AM5QCsjsKEdo62at6FihRV5df9iwgHYjQUAFBP23Lg2keKASg62cDIpdzrx1hExtduAXZ7tgKqNiv28-7PEUQLbd013VQ-pHXGwh7kA40xzFgaNqEKPY9nnlJ4HL6qifOh9VSslDzCkT8SdKQSrDOh0xgkMT3wfNKqJmyBo1gNc2G-i524bJMpLnvyBvDAQ1Wvc03Gmbv3-PJvrNHl4BDaCqqZbMIr3Go55BNkKfPIkfK-NNGGOxPU60KhNr&c=czuTgqhHhCX9iP5o0Q5mcRcHV3SagccZrpULyCmP4DfTL9hl5P1PaQ==&ch=sO08VZ_qVBLDNsdD4ZQD0sbCs_P0IKsa6N5Zoukh44I2ONPBFFXSKA==>

What’s new in the guidelines

This update incorporates new evidence published since the 2016 HIV nonoccupational postexposure prophylaxis (nPEP) guidelines, including evidence related to safety and tolerability of newer antiretroviral (ARV) medications. Highlighted updates from the 2016 guideline recommendations include the following:
·     Expanded discussion of nPEP indications, now including situations in which the source (e.g., a person with HIV) has consistent viral suppression, in which the person exposed has been taking HIV pre-exposure prophylaxis (PrEP), and in which the known or possible exposure occurred due to sexual assault (see HIV nPEP Indications).
·     Increased emphasis on the urgency of nPEP initiation including optimal administration within the first 24 hours after exposure (see Time to Initiation of HIV nPEP).
·     Updated preferred regimens: The preferred regimens for most adults and adolescents are now bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) OR dolutegravir (DTG) plus tenofovir alafenamide (TAF) OR tenofovir disoproxil fumarate (TDF) plus emtricitabine (FTC) OR lamivudine (3TC). Guidance about preferred and alternative regimens for adults and adolescents, children, and pregnant women, and regimens for persons with renal or hepatic dysfunction also is provided (see HIV nPEP Regimens).
·     Updated clinical considerations for laboratory testing including considerations for use of diagnostic HIV nucleic acid tests (NATs) along with HIV antigen/antibody tests (Ag/Ab tests) in certain clinical scenarios; emphasis on not delaying nPEP initiation while awaiting laboratory testing; update to routine follow-up testing of serum creatinine, alanine aminotransferase (ALT), and aspartate aminotransferase (AST), indicating that it is not necessary unless baseline tests are abnormal or other specific clinical indications are present; and updates to testing for other clinical conditions such as other sexually transmitted infections (STIs) (see Laboratory Testing and nPEP Follow-Up).
·     Emphasis on the need for HIV PrEP education for all persons assessed for nPEP, and the need for an nPEP-to-PrEP transition plan when indicated, including the possibility of an immediate PEP-to-PrEP transition for persons with substantial likelihood of HIV acquisition who might benefit from this approach (see Transitioning to PrEP after PEP).

------

[https://files.constantcontact.com/980d1efb101/b47afddb-b616-4e40-aa3e-f5871e0a5807.png?rdr=true]

Download Document<https://jeud54gab.cc.rs6.net/tn.jsp?f=001-7EhbBdSupsnaD1lwRUP5h3I6uUPSHxAJ2g3MFNUqcxNpTmfHKKV46cqA32fZrCB91KkCgidvmVzjS30vhKkAUaUz9qXD0Qpd5j145U1TN-3kob8g2mVsOwn9ZpJgU_UJa8Udrw9Ix5cGu9TzsLNuJhKy0k5hKZVFkpmQJnPBg4ffhsTqSAoWS-zoiVP-OpO5ckyqDT5MzvLl5wXIXKgqjvzWWuB7SSDcKo0nA0lwT8=&c=czuTgqhHhCX9iP5o0Q5mcRcHV3SagccZrpULyCmP4DfTL9hl5P1PaQ==&ch=sO08VZ_qVBLDNsdD4ZQD0sbCs_P0IKsa6N5Zoukh44I2ONPBFFXSKA==>

________________________________

Shelley Pearson
Pronouns: she/her/hers
HIV/STI Administrative and Communications Specialist
OREGON HEALTH AUTHORITY
Public Health Division
shelley.m.pearson at oha.oregon.gov<mailto:shelley.m.pearson at dhsoha.state.or.us>
Phone: 503-381-6173
Fax: 971-673-0178

[cid:image001.png at 01DBBF52.E5664570]<http://www.endhivoregon.org/>

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <https://omls.oregon.gov/pipermail/hiv-std-prevention/attachments/20250507/457ccb82/attachment-0001.html>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image001.png
Type: image/png
Size: 17451 bytes
Desc: image001.png
URL: <https://omls.oregon.gov/pipermail/hiv-std-prevention/attachments/20250507/457ccb82/attachment-0001.png>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: 2025-single subject flier-congenital syphilis-may 2025.pdf
Type: application/pdf
Size: 334766 bytes
Desc: 2025-single subject flier-congenital syphilis-may 2025.pdf
URL: <https://omls.oregon.gov/pipermail/hiv-std-prevention/attachments/20250507/457ccb82/attachment-0001.pdf>